Breaking News Instant updates and real-time market news.

AMRN

Amarin

$11.13

8.13 (271.00%)

, SNY

Sanofi

$43.33

-0.28 (-0.64%)

14:48
09/24/18
09/24
14:48
09/24/18
14:48

Amarin CEO says Vascepa 'more analogous' to statins than PCSK9 inhibitors

Amarin CEO John Thero said his company's omega-3 pill Vascepa is "more analogous" to statins, which address a broad market, than to PCSK9 inhibitor's such as Sanofi (SNY) and Regeneron's (REGN) Praluent, which address a narrower market. Asked about pricing of Vascepa, Thero said he believes it is appropriate for the drug to be priced similar to how statins were priced prior to generic versions being made available. Thero made the comments while being interviewed on CNBC.

AMRN

Amarin

$11.13

8.13 (271.00%)

SNY

Sanofi

$43.33

-0.28 (-0.64%)

REGN

Regeneron

$388.88

-1.67 (-0.43%)

  • 24

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 20

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

AMRN Amarin
$11.13

8.13 (271.00%)

09/24/18
CANT
09/24/18
NO CHANGE
Target $15
CANT
Overweight
Cantor Fitzgerald raises Amarin price target to $15 after REDUCE-IT meets goal
Cantor Fitzgerald analyst Louise Chen raised her price target on Amarin shares to $15 from $10 after increasing her Vascepa peak sales estimate to $1.1B from $648.2M following the topline data release from the REDUCE-IT trial. The data "prove that EPA is different than other omega-3s" and there is not other drug like Vascepa out today, said Chen, who maintains an Overweight rating on Amarin shares.
08/06/18
CANT
08/06/18
NO CHANGE
Target $10
CANT
Overweight
Amarin risk/reward favorable ahead of Q3 data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen views the risk/reward for Amarin shares as favorable ahead of what she expects will be positive results for its Reduce-It outcomes study. Positive results from the study, which are expected by the end of Q3, should drive upward earnings revisions to levels not reflected in consensus numbers and the stock higher, Chen tells investors in a research note. The Street thinks Reduce-It will fail, the analyst adds. She affirms an Overweight rating on Amarin with a $10 price target.
08/27/18
CANT
08/27/18
NO CHANGE
Target $10
CANT
Overweight
Ascend trial outcome does not mean Amarin study will fail, says Cantor
Cantor Fitzgerald analyst Louise Chen says that as expected, the omega-3 arms of the Ascend trial, sponsored by Oxford University and British Heart Foundation, did not demonstrate a reduction of first serious vascular events with the therapy of omega-3 fatty acid supplementation studied. The analyst does not think this means that Amarin's Reduce-It study will not show a benefit for patients. Because Ascend was expected to be negative, an overhang has now been removed ahead of the Reduce-It readout, Chen tells investors in a research note. She thinks now is a good time to take another look at Amarin shares given the upcoming potential catalyst. Chen has an Overweight rating on Amarin with a $10 price target. This post corrects the headline as the Ascend study was not run by Amarin as previously stated.
09/24/18
SBSH
09/24/18
NO CHANGE
Target $5
SBSH
Buy
Citi sees about five times upside for Amarin after Vascepa trial succeeds
Citi analyst Joel Beatty said he views Amarin as a "strong acquisition candidate" after the REDUCE-IT outcomes trial of Vascepa succeeded and noted that he previously stated that Amarin could be worth $14 per share in this scenario. The 25% RRR on the primary endpoint exceeded his expectations as well as that of "most bulls," contends Beatty, who has a Buy rating and $5 price target on the stock. Near noon, Amarin shares are up 238% to $10.12.
SNY Sanofi
$43.33

-0.28 (-0.64%)

09/10/18
MSCO
09/10/18
INITIATION
Target $72
MSCO
Overweight
MyoKardia initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung initiated MyoKardia (MYOK) at Overweight with a $72 price target, stating that the obstructive hypertrophic cardiomyopathy Phase 2 data for its lead program, mavacamten, were "robust" and the fact that the company is partnered with Sanofi (SNY) gives him incremental confidence. He expects a mavacamten launch in oHCM in early 2022 and peak U.S. sales for the drug of greater than $1.3B.
09/14/18
LSCM
09/14/18
NO CHANGE
Target $90
LSCM
Buy
Apple Watch more likely a positive for BioTelemetry, says Lake Street
After spending time with Joe Capper and Heather Getz, CEO and CFO of BioTelemetry (BEAT), Lake Street analyst Brooks O'Neil senses that Apple's (AAPL) Watch Series 4, which includes a built-in electrocardiogram, is more likely a positive for BioTelemetry "than a buzzer sounding a flat-line for the company's future." BioTelemetry remains the leading cardiac monitoring company and this is likely to continue for the foreseeable future, O'Neil tells investors in a research note. He points out the company has a partnership with Apple in cardiac monitoring and with Sanofi (SNY) and Alphabet (GOOG) in diabetes. The analyst's guesses that its partnership is one element giving BioTelemetry management comfort in evaluating the role Apple might play in the company's future. O'Neil reaffirms a Buy rating on the shares with a $90 price target.
09/10/18
BOFA
09/10/18
UPGRADE
BOFA
Buy
Sanofi upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Parry upgraded Sanofi to Buy from Neutral saying the company is approaching an inflection in growth from new products, mainly Dupixent, atopic, dermatitis, while diabetes becomes less of a headwind. Parry believes sales and earnings growth will accelerate to 7% from 4% in through 20-2023E and views valuation as undervaluing growth.
09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
REGN Regeneron
$388.88

-1.67 (-0.43%)

08/08/18
PIPR
08/08/18
NO CHANGE
PIPR
Overweight
Piper says CMS Part B headlines 'scary,' but Regeneron pullback an overreaction
Piper Jaffray analyst Christopher Raymond said he would be a buyer on weakness in shares of Regeneron after CMS announced new rules giving Medicare Advantage plans the option of implementing "step therapy" to introduce competition. He checked in with leading drug pricing and reimbursement experts, whose view is that this may drive discounting and competition between Eylea and Lucentis, much like what exists today with private pay plans. After speaking with management, Raymond estimates about 3.4% of 2019 Eylea revenue is at risk. Assuming Regeneron has to price at Eylea at a 30% discount translates to a roughly $40M revenue impact and a 36c, or 1.5%, hit to EPS in 2019, said Raymond, who called the 6% pullback in the stock an overreaction in light of those estimates. He maintains an Overweight rating on Regeneron shares.
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
08/16/18
PIPR
08/16/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron's fasinumab safety remains 'open question,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond backed an Overweight rating on Regeneron Pharmaceuticals (REGN) shares following this morning's release of fasinumab results, saying the drug and partner Teva's (TEVA) anti-NGF antibody met its primary and secondary efficacy pain and functional endpoints in a Phase 3 trial of patients with chronic pain from osteoarthritis of the knee or hip. Raymond says the efficacy "was never really in doubt," but the bigger focus for the drug is safety, and will wait for detailed data at an upcoming medical meeting, but notes that fasinumab's arthropathy rate appears "slightly higher" than that of tanezumab. Given the severity of the ongoing opioid epidemic and relative lack of alternatives for these patients outside of total joint replacement, the analyst thinks the appetite of regulators and potential market for new effective, non-opioid chronic pain therapies like anti-NGF clearly exists, though he will leave this as an unmodeled potential source of upside for now,

TODAY'S FREE FLY STORIES

01:40
10/19/18
10/19
01:40
10/19/18
01:40
General news
Asian Market Wrap: »

Asian Market Wrap:…

22:20
10/18/18
10/18
22:20
10/18/18
22:20
General news
China's GDP slowed to a 6.5% y/y growth pace in Q3 »

China's GDP slowed…

NI

NiSource

$25.25

0.22 (0.88%)

21:12
10/18/18
10/18
21:12
10/18/18
21:12
Downgrade
NiSource rating change at Goldman Sachs »

NiSource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PNW

Pinnacle West

$83.48

-0.235 (-0.28%)

21:04
10/18/18
10/18
21:04
10/18/18
21:04
Upgrade
Pinnacle West rating change at Goldman Sachs »

Pinnacle West upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 11

    Nov

  • 11

    Nov

NVS

Novartis

$86.24

0.9 (1.05%)

20:26
10/18/18
10/18
20:26
10/18/18
20:26
Hot Stocks
Novartis granted orphan status for melanoma treatment »

The FDA granted Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

, HON

Honeywell

$155.22

-2.73 (-1.73%)

20:25
10/18/18
10/18
20:25
10/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

HON

Honeywell

$155.22

-2.73 (-1.73%)

SLB

Schlumberger

$58.43

-0.81 (-1.37%)

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

STT

State Street

$79.62

-2.5 (-3.04%)

STI

SunTrust

$61.46

-0.94 (-1.51%)

SYF

Synchrony

$29.63

-0.45 (-1.50%)

CFG

Citizens Financial

$34.92

-0.96 (-2.68%)

KSU

Kansas City Southern

$102.68

-1.31 (-1.26%)

IPG

Interpublic Group

$22.48

0.28 (1.26%)

EEFT

Euronet

$112.64

-2.96 (-2.56%)

MAN

Manpower

$78.38

-1.09 (-1.37%)

GNTX

Gentex

$18.62

-0.32 (-1.69%)

CLF

Cleveland-Cliffs

$11.47

-0.37 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 24

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 26

    Nov

  • 26

    Nov

  • 06

    Dec

  • 03

    Mar

CP

Canadian Pacific

$199.27

-6.68 (-3.24%)

20:24
10/18/18
10/18
20:24
10/18/18
20:24
Upgrade
Canadian Pacific rating change at National Bank »

Canadian Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

DWDP

DowDuPont

$58.60

-0.98 (-1.64%)

19:57
10/18/18
10/18
19:57
10/18/18
19:57
Hot Stocks
DowDuPont clarifies the charge is the result of previously reported conditions »

In response to market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

19:35
10/18/18
10/18
19:35
10/18/18
19:35
Downgrade
Valero Energy Partners rating change at RBC Capital »

Valero Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

IVZ

Invesco

$21.26

0.32 (1.53%)

19:33
10/18/18
10/18
19:33
10/18/18
19:33
Downgrade
Invesco rating change at Credit Suisse »

Invesco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

LOGC

LogicBio Therapeutics

$0.00

(0.00%)

19:31
10/18/18
10/18
19:31
10/18/18
19:31
Syndicate
LogicBio Therapeutics 7M share IPO priced at $10.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MDSO

Medidata

$70.91

1.54 (2.22%)

19:07
10/18/18
10/18
19:07
10/18/18
19:07
Recommendations
Medidata analyst commentary at JPMorgan »

Medidata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$263.85

-8.09 (-2.97%)

18:58
10/18/18
10/18
18:58
10/18/18
18:58
Periodicals
Tesla rolls out new Model 3 with 'mid-range' battery pack, Electrek reports »

Tesla today is rolling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Dec

SKX

Skechers

$26.05

-0.64 (-2.40%)

, PYPL

PayPal

$77.50

-2.61 (-3.26%)

18:51
10/18/18
10/18
18:51
10/18/18
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$26.05

-0.64 (-2.40%)

PYPL

PayPal

$77.50

-2.61 (-3.26%)

CE

Celanese

$97.01

-2.76 (-2.77%)

CP

Canadian Pacific

$199.27

-6.68 (-3.24%)

ISRG

Intuitive Surgical

$522.41

-20.44 (-3.77%)

AXP

American Express

$102.86

-1.53 (-1.47%)

ETFC

E-Trade

$48.89

-1.68 (-3.32%)

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

VLO

Valero

$103.31

-0.36 (-0.35%)

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

OZK

Bank OZK

$34.85

-1.57 (-4.31%)

LLNW

Limelight Networks

$5.07

0.12 (2.42%)

TEAM

Atlassian

$81.96

-1.67 (-2.00%)

AIG

AIG

$48.62

-0.99 (-2.00%)

SREV

ServiceSource

$2.60

-0.08 (-2.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 29

    Oct

  • 29

    Oct

  • 05

    Nov

  • 07

    Nov

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 05

    Dec

  • 06

    Dec

X

U.S. Steel

$27.91

-0.27 (-0.96%)

, AKS

AK Steel

$4.69

-0.115 (-2.39%)

18:47
10/18/18
10/18
18:47
10/18/18
18:47
Periodicals
U.S. requests WTO panel to examine metals tariffs retaliation, Reuters says »

The U.S. has asked the…

X

U.S. Steel

$27.91

-0.27 (-0.96%)

AKS

AK Steel

$4.69

-0.115 (-2.39%)

NUE

Nucor

$58.26

-0.85 (-1.44%)

STLD

Steel Dynamics

$41.32

0.77 (1.90%)

AA

Alcoa

$38.85

2.14 (5.83%)

CENX

Century Aluminum

$9.91

-0.23 (-2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 25

    Oct

  • 26

    Oct

  • 02

    Nov

RLH

Red Lion Hotels

$12.62

-0.42 (-3.22%)

18:43
10/18/18
10/18
18:43
10/18/18
18:43
Hot Stocks
Red Lion Hotels CFO Douglas Ludwig resigns due to personal health reasons »

RLH Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

IDA

IDACORP

$96.78

0.035 (0.04%)

18:30
10/18/18
10/18
18:30
10/18/18
18:30
Hot Stocks
IDACORP declares quarterly dividend of 63c per share »

Director of IDACORP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$20.70

-0.59 (-2.77%)

18:08
10/18/18
10/18
18:08
10/18/18
18:08
Syndicate
Krystal Biotech 3M share Secondary priced at $20.00 per share »

Cowen, William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

, SVU

Supervalu

$32.49

0.02 (0.06%)

18:05
10/18/18
10/18
18:05
10/18/18
18:05
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

SVU

Supervalu

$32.49

0.02 (0.06%)

UNFI

United Natural Foods

$26.94

0.2 (0.75%)

TTGT

TechTarget

$19.53

-0.35 (-1.76%)

PERY

Perry Ellis

$27.48

0.02 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 23

    Oct

  • 28

    Oct

  • 07

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

SXT

Sensient

$76.67

-1.15 (-1.48%)

18:02
10/18/18
10/18
18:02
10/18/18
18:02
Hot Stocks
Sensient raises quarterly dividend to 36c from 33c per share »

The cash dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DWDP

DowDuPont

$58.60

-0.98 (-1.64%)

18:02
10/18/18
10/18
18:02
10/18/18
18:02
Hot Stocks
DowDuPont says Sept. quarter results won't be impacted by $4.5B goodwill charge »

On October 18, 2018, E.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$3.54

-0.13 (-3.54%)

17:55
10/18/18
10/18
17:55
10/18/18
17:55
Hot Stocks
Northern Oil and Gas sees Q4 production 58% greater than Q2 »

Liquidity has increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SHPG

Shire

$176.90

-0.4 (-0.23%)

17:47
10/18/18
10/18
17:47
10/18/18
17:47
Hot Stocks
FDA advisory committee recommends Shire's Prucalopride for CIC »

Shire announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 21

    Dec

ACN

Accenture

$156.20

-2.76 (-1.74%)

, T

AT&T

$32.50

-0.06 (-0.18%)

17:37
10/18/18
10/18
17:37
10/18/18
17:37
Hot Stocks
CACI, IBM, Northrop Grumman and more compete for orders on $37.4B Army contract »

Accenture Federal…

ACN

Accenture

$156.20

-2.76 (-1.74%)

T

AT&T

$32.50

-0.06 (-0.18%)

CACI

CACI

$181.34

-2.07 (-1.13%)

HII

Huntington Ingalls

$233.27

0.15 (0.06%)

CMTL

Comtech

$32.05

-0.95 (-2.88%)

IBM

IBM

$130.52

-3.53 (-2.63%)

JEC

Jacobs Engineering

$73.01

-0.89 (-1.20%)

KFRC

Kforce

$35.15

-0.49 (-1.37%)

LLL

L3 Technologies

$218.17

-1.965 (-0.89%)

LDOS

Leidos

$66.72

-0.97 (-1.43%)

NOC

Northrop Grumman

$308.21

-1.04 (-0.34%)

RTN

Raytheon

$191.62

-1.48 (-0.77%)

KEYW

KEYW

$8.31

-0.27 (-3.15%)

VSEC

VSE Corp.

$30.75

-1.13 (-3.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 03

    Mar

UBSFY

Ubisoft

$0.00

(0.00%)

, BBY

Best Buy

$72.63

-1.2 (-1.63%)

17:31
10/18/18
10/18
17:31
10/18/18
17:31
Periodicals
Certain boxes of new Ubisoft game from Best Buy didn't include game, Kotaku says »

A number of Best Buy…

UBSFY

Ubisoft

$0.00

(0.00%)

BBY

Best Buy

$72.63

-1.2 (-1.63%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.